Menopausal obesity - Myth or fact?

Climacteric

Volumn 4, Issue 4, 2001, Pages 273-283

  Milewicz, A ^a   Tworowska, U ^a   Demissie, M ^a  

^a NONE   (Poland)

Author keywords

Aging; Hormone therapy; Menopause; Obesity

Indexed keywords

ESTROGEN; GROWTH HORMONE; NEUROPEPTIDE; PRASTERONE; SOMATOMEDIN;

AGING; CALORIC INTAKE; DIET; DISEASE ASSOCIATION; ENERGY EXPENDITURE; FEMALE; HORMONE BLOOD LEVEL; HUMAN; MENOPAUSE; METABOLIC DISORDER; OBESITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; WEIGHT GAIN;

EID: 0035662401     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/cmt.4.4.273.283     Document Type: Review

References (128)

1. Body weight and mortality among women
2. Sex- and menopause-associated changes in body fat distribution
3. Body weight, fat distribution and the menopausal status in women
4. Relative influence of age and menopause on total and regional body composition changes in postmenopausal women
5. Total and regional body composition changes in early postmenopausal women: Age related or menopause related?
6. Aging in women - The four-compartment model of body composition
7. Age- and menopause-associated variations in body composition and fat distribution in healthy women as measured by dual-energy X-ray absorptiometry
8. Weight gain at the time of the menopause
9. Sexual dimorphism of age related changes of whole body fat distribution in the obese
10. Climacteric modifications in body weight and fat tissue distribution
11. Weight gain and the menopause: A 5-years prospective study
12. Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease
13. Effect of aging on body fat
14. Postmenopausal weight status, body composition and body fat distribution in relation to parameters of menstrual and reproductive history
15. Relation of body fat distribution to reproductive factors in pre- and postmenopausal women
16. Etiology and pathogenesis of obesity
17. Metabolic rate and physical development in children at risk of obesity
18. Reduced rate of energy expenditure as a risk factor for body weight gain
19. Determinants of 24-hour energy expenditure in man
20. Aging, basal metabolic rate, and nutrition
21. Aging and energy expenditure
22. Is there evidence for an age-related reduction in metabolic rate?
23. Two-week stimulation or blockade of the sympathetic nervous system in man: Influence on body weight, body composition, and twenty four-hour energy expenditure
24. Ethnic differences in sympathetic nervous system-mediated energy expenditure
25. Reduced sympathetic nervous activity. A potential mechanism predisposing to body weight gain
26. Thermic effect of food in humans: Methods and results from use of respiratory chamber
27. The sympathetic nervous system and obesity: Role in aetiology and treatment
28. Sympathoadrenal activity in human obesity: Heterogeneity and findings since 1980
29. A low sympathetic nervous system activity is associated with body weight gain in Pima Indians
30. Gender difference in age-related changes in muscle sympathetic nerve activity in healthy subjects
31. Age-related increase in muscle sympathetic nerve activity is associated with abdominal adiposity
32. Autonomic nervous system function
33. Exercise, substrate utilisation and energy requirements in the elderly
34. Sympathetic nervous system activity and α-adrenergic responsiveness in older hypertensive humans
35. Inheritance of the amount and distribution of human body fat
36. A role for brown adipose tissue in diet-induced thermogenesis
37. 3-adrenergic receptors and obesity
38. 3-adrenoceptor gene variant in postmenopausal women
39. 3-adrenoceptor and insulin resistance in obese postmenopausal women
40. Association between uncoupling protein polymorphisms (UCP2-UCP3) and energy metabolism/obesity in Pima Indians
41. Positioning cloning of the mouse obese gene and its human homologue
42. Congenital leptin deficiency is associated with severe early-onset obesity in humans
43. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction
44. Obesity associated with a mutation in genetic regulator of adipocyte differentiation
45. Adipogenesis: Rounding out the big picture
46. Association of estrogen receptor-α genotypes with body mass index in normal healthy postmenopausal Caucasian women
47. Perimenopausal obesity
48. Neuroendocrine control of development of obesity: Understanding gained from studies of experimental animal models
49. Neuropeptide regulation of appetite and weight
50. Brain monoamines and peptides: Role in the control of eating behaviour
51. Recombinant mouse ob protein: Evidence for a peripheral signal linking adiposity and central neural networks
52. Effects of gender, body composition, and menopause on plasma concentrations of leptin
53. Estrogen increases in vivo leptin production in rats and human subjects
54. Cholecystokinin and estradiol synergistically potentate satiety in rats
55. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels
56. Endogenous/exogenous estrogens satiety plus appetite stimulating peptides in women
57. 17β-estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: A potential mechanism for the antiosteoporotic effect of estrogens
58. Hormone replecement therapy and interaction between serum interleukin-6 and body mass index in postmenopausal women: A population study
59. The endocrinology of aging
60. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal estrogen/progestin interventions study investigators
61. Estrogen/gestagen therapy changes soft tissue body composition in postmenopausal women
62. Fat distribution in relation to age, degree of obesity, smoking habits, parity and estrogen use: A cross-sectional study in 11 824 Dutch women participating in the DOM-project
63. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women
64. Association of body fat distribution, circulating sex hormones, and bone density in postmenopausal women
65. Endocrine abnormalities of obesity
66. The regulation of adipose tissue distribution in humans
67. Adipose tissue as an endocrine and paracrine organ
68. Fat cell metabolism in different regions in women. Effects of menstrual cycle, pregnancy and lactation
69. The effects of steroid hormones on adipocyte development
70. Glucocorticoid binding of human adipose tissue
71. Human control of regional fat distribution
72. Long-term testosterone administration increases visceral fat in female-to-male transsexuals
73. Exogenous androgens influence body composition and regional body fat distribution in obese postmenopausal women - A clinical research centre study
74. The role of DHEA in obesity
75. The antiobesity effect of dehydroepiandrosterone in rats
76. Is dehydroepiandrosterone an antiobesity agent?
77. Obesity in the dog: Role of the adrenal steroid dehydroepiandrosterone (DHEA)
78. Therapeutic effects of dehydroepiandrosterone (DHEA) in diabetic mice
79. Relationship of dehydroepiandrosterone sulfate in elderly with functional psychological and mental status and short term mortality: A French community-based study
80. Age changes and sex differences in serum dehydroepiandrosterone sulphate content throughout adulthood
81. Dehydroepiandrosterone sulphate, incidence of myocardial infarction and extent of atherosclerosis in men
82. Dehydroepiandrosterone reduces serum low density lipoprotein levels and body fat, but does not alter insulin sensitivity in normal men
83. Replacement of DHEA in ageing men women: Potential remedial effects
84. DHEA improves lean body mass of older men
85. Metabolic effects of 12-months percutaneous dehydroepiandrosterone replacement therapy in postmenopausal women
86. Chronic administration of dehydroepiandrosterone reduces pancreatic β-cell hyperplasia and hyperinsulinemia in genetically obese Zucker rats
87. Effects of replacement doses of dehydroepiandrosterone in men and women of advancing age
88. Metabolic and hormonal changes after DHEA treatment
89. Effects of growth hormone on body fat in adults
90. GH replacement in 1034 growth hormone deficient hypopituitary adults: Demographic and clinical characteristics, dosing and safety
91. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism
92. Effects of growth hormone on fat mass and fat distribution
93. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review
94. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency
95. Growth hormone gene expression and secretion in ageing rats is age dependent and not age-associated weight increase related
96. Age and related adiposity are specific negative determinants of the frequency and amplitude of growth hormone (GH) secretory bursts and the half-life of endogenous GH in healthy men
97. Relationship between age, percentage body fat, fitness and 24-hour growth hormone release in healthy young adults: Effects of gender
98. Age-related decrease in plasma growth hormone: Response to growth hormone-releasing hormone, arginine, and L-dopa in obesity
99. Insulin-like growth factors and ageing
100. Skeletal growth factors and ageing
101. The influence of obesity on health
102. Obesity: Adverse effects on health and longevity
103. Variations in mortality by weight among 750 000 men and women
104. Insulin resistance
105. Abdominal obesity and the development of non-insulin dependent diabetes mellitus
106. Biology of regional body fat distribution: Relationship to non-insulin dependent diabetes mellitus
107. Role of insulin resistance in human disease
108. Obesity as an independent risk factor for cardiovascular disease: A 26-year follow-up of participants in the Framingham heart study
109. Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13-year follow-up of participants in the study of men born in 1913
110. Distribution of adipose tissue and risk of cardiovascular disease and death: A 12 year follow-up of participants in the population study of women in Gothenburg, Sweden
111. Obesity and risk of cardiovascular disease
112. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from lipid research clinics program follow-up study
113. Comparison of transdermal and oral estrogen/progestin hormone replacement therapy: Effect on serum lipids and lipoproteins
114. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of lipoproteins
115. Effects of hormone replacement on lipids and lipoproteins in postmenopausal women
116. Long-term influence of different hormone replacement regiments on serum lipids and lipoprotein(a): A randomised study
117. Reproductive history in relation to relative weight and fat distribution
118. Body fat distribution, the menopause transition, and hormone replacement therapy
119. Long-term postmenopausal hormone use, obesity, and fat distribution in older women
120. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial
121. The influence of menopause and hormonal replacement therapy on body cell mass and body fat mass
122. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause
123. Oestrogen and progestogen hormone replacement therapy for peri-menopausal and post-menopausal women: Weight and body fat distribution
124. Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women
125. A longitudinal study of weight and the menopause transition: Results from the Massachusetts Women's Health Study
126. Prevention of cardiovascular risk factor elevations in healthy premenopausal women
127. Maintenance of cardiovascular risk factor changes among middle-aged women in a lifestyle intervention trial